Alamar Biosciences, Inc. · NASDAQ:ALMR

Alamar Biosciences — BofA Healthcare Conference 2026

27 slides from Alamar Biosciences's conference presentation, May 12, 2026

Slide 1: BofA Healthcare Conference Presentation
JP Morgan Healthcare Conference BofA Healthcare Conference Presentation May 12, 2026 ©2026 Alamar Biosciences, Inc.
Slide 2: Disclaimers
Disclaimers Certain information contained in this presentation relates to or is based on studies, publications, surveys, and other data obtained from third-party sources and the internal estimates and research of Alamar Biosciences, Inc. (the “Company,” “Alamar,” “we,” “us,” or “our”). While the Com
Slide 3: Proteomics is the new frontier in human biology and precision medicine
Proteomics is the new frontier in human biology and precision medicine For the first time, we have the technology to unlock its full potential ‹#› 3 ©2026 Alamar Biosciences, Inc.
Slide 4: Powering precision proteomics to enable the earliest detection of disease
OUR MISSION Powering precision proteomics to enable the earliest detection of disease 4 ©2026 Alamar Biosciences, Inc.
Slide 5: Fastest commercial ramp in proteomics
Fastest commercial ramp in proteomics $74M >100 >$400K 2025 Total Revenue Instrument Installed Base1 Average Annual Instrument Pull-through2 1. Cumulative instrument installed base as of December 31, 2025. ‹#› 5 2. As of December 31, 2025. ©2026 Alamar Biosciences, Inc.
Slide 6: Q1 2026 revenue nearly doubles year-over-year
Q1 2026 revenue nearly doubles year-over-year $26.0M Q1 2026 Total revenue increased 99% compared to Q1 2025 $13.1M Gross margin of 56% compared to 49% in Q1 2025 Q1 2025 Q1 2026 ‹#› 6 ©2026 Alamar Biosciences, Inc.
Slide 7: Massive and rapidly expanding proteomics opportunity
Massive and rapidly expanding proteomics opportunity Total Proteomics Market (Estimated 2035) Includes all proteomics-related spend for research and clinical Dx ~$80B Advanced Proteomics (Estimated 2035) Significant growth expected from existing and new clinical Dx use ~$20B Advanced Proteomics (202
Slide 8: Establishing a gold standard in precision proteomics
Establishing a gold standard in precision proteomics ARGO HT Consumables Software All-in-one instrument Simple, robust, reproducible From samples to insights ‹#› 8 ©2026 Alamar Biosciences, Inc.
Slide 9: Combining all five pillars required for precision proteomics
Combining all five pillars required for precision proteomics Ultra-high High Flexible Broad Seamless Sensitivity Specificity Multiplex Dynamic Automation Range >10 – 250X Proteoforms 1 – 1,000s Up to 12 Logs <30 Minutes Improvement E.g., post-translational Plex capabilities Range without dilution Ha
Slide 10: NULISA technology is designed to set a new standard in performance
NULISA technology is designed to set a new standard in performance 10,000x Background suppression and signal-to-noise improvement1 ‹#› 10 1. Compared to conventional immunoassays ©2026 Alamar Biosciences, Inc.
Slide 11: Our platform: Precision Proteomics
Our platform: Precision Proteomics Future Expansion Current Scope Single or low-plex Excellent diagnostic NULISA technology Analytic performance (PLASMA) immunoassays Low-plex research use immunoassays Moderate Mid-plex discovery platforms Highly multiplexed discovery platforms Subpar Kilo-plex Cent
Slide 12: One platform enabling end-to-end proteomics from discovery to diagnostics
One platform enabling end-to-end proteomics with seamless translation from discovery to diagnostics Broad Alamar’s Focused Profiling Market Entry Analysis Discovery Targeted Translation Clinical >1,000 plex 100 – 1,000 plex 10 – 100 plex 1 – 10 plex Hypothesis-free Discovery for Validation of For bi
Slide 13: Building category leadership using a proven playbook
Building category leadership using a proven playbook Expand into Early Detection and Prevention Drive Expand User Adoption Base Engage Broad Commercial KOLs Release Demonstrate Capabilities Early Access • Launch Program • Establish beachhead additional Technology Access panels & • Market penetration
Slide 14: Exceptional growth in a challenging macro environment
Exceptional growth in a challenging macro environment Total Revenue $74M Consumables were ~50% of our total revenue in 2025 Biopharma contributed ~44% of 2025 revenue1 $25M $3M 2023 2024 2025 1. Includes biopharma and CRO/clinical customers ‹#› 14 ©2026 Alamar Biosciences, Inc.
Slide 15: Example of a top pharma's journey in platform adoption
Example of a top pharma's journey in platform adoption Applications across: Biomarker discovery Clinical trial cohort studies Custom assay development ARGO #1 ARGOs #2 & #3 ARGO #4 ARGOs #5 & #6 TAP Services Q4 ‘23 Q1 ‘24 Q2 ‘24 Q3 ‘24 Q4 ‘24 Q1 ‘25 Q2 ‘25 Q3 ‘25 Q4 ‘25 Q1 ‘26 ‹#› 15 ©2026 Alamar Bi
Slide 16: Strong and rapidly growing scientific publications
Strong and rapidly growing scientific publications 124 Publications & pre-prints NEUROLOGY INFLAMMATION since commercial launch ONCOLOGY AND MORE… Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 ‹#› 16 Source: Chart of cumulative customer peer-reviewed publications and pre-pr
Slide 17: Collaborating with some of the world's most influential neuro foundations
Collaborating with some of the world’s most influential neuro foundations Novel biomarker discovery with CNS disease and inflammation panels Dx enablement >40K Samples >23K Samples >3K PPMI Samples $10M Funding One of the largest Longitudinal aging Deepen understanding Accelerate the cohorts linked
Slide 18: Accelerating growth through a highly efficient sales team
Accelerating growth through a highly efficient sales team Scalable sales and support structure to ensure top-tier customer experience Field Application Scientist Field Service Inside Sales Engineer Specialist Regional Business Manager Population Health Pharma Direct Business Business Development Dev
Slide 19: Driving adoption and expansion over the next 12 months
Driving adoption and expansion over the next 12 months Commercial Novel Content Use Cases & Organization Expansion Applications Maintain highly efficient Further extend leadership in Collaborate with commercial organization neurology & inflammation customers to develop new while expanding team and a
Slide 20: Building a portfolio of differentiated assay content
Building a portfolio of differentiated assay content to address clear unmet needs 4 1 2 3 Combine novel and Be the leader in Enable translation Become the partner low abundance multiplexed panels with customization / platform of choice proteome content with unique, and low-plex formats for LDT and I
Slide 21: Customer-driven menu expansion across continuum from discovery to clinical
Customer-driven menu expansion across continuum from discovery to clinical biomarkers AD 5-Plex BIOMARKERS BD-pTau217 CLINICAL NfL IL4 TRANSLATION Custom Assay Development Kits Neuro 220 Mouse 120 Inflammation AQ DISCOVERY TARGETED CNS Disease 120 Inflammation 250 2024 2025 2026 ‹#› 21 ©2026 Alamar
Slide 22: Raising the bar with Neuro 220
Raising the bar with Neuro 220 15 new biomarkers developed with support from The Michael J. Fox Foundation for Parkinson’s Research 17 Proteins (9 new) 25 Proteins 39 Proteins (10 new) (10 new) ALS, HD Ataxia Multiple Inflammation Sclerosis & Neuro 104 Proteins Alzheimer's Parkinson’s 38 Proteins Di
Slide 23: What differentiates our model from other LS tools?
What differentiates our model from other LS tools? Industry-leading pull-through Clear path to future clinical applications Strong and growing biopharma customer base Already a key tool for Alzheimer’s disease Broad applicability across nearly every disease ‹#› 23 ©2026 Alamar Biosciences, Inc.
Slide 24: Seasoned leaders with a proven track record of success
Seasoned leaders with a proven track record of success Yuling Luo, PhD Tod White, JD Steve Chen, PhD Xiao-Jun Ma, PhD Justin McAnear Founder, CEO President Founder, COO & Chief Technology Chief Financial Officer & Chairman Director Officer Stephen Williams, Anna Berdine Alex Forrest-Hay Micah Litow
Slide 25: Our growth strategy to lead the proteomics era
Our growth strategy to lead the proteomics era Grow our global installed base Develop novel targeted panels Enable LDT and IVD use of the platform Broaden access to smaller and emerging labs Create an ecosystem for proteomics ‹#› 25 ©2026 Alamar Biosciences, Inc.
Slide 26: Alamar is well-positioned to lead precision proteomics
Alamar is well-positioned to lead precision proteomics Highly differentiated platform enabling discovery to potential clinical Dx Fastest adoption among advanced proteomics companies Track record of execution and value creation $74M >100 >$400K >120 2025 Total Instrument Average Annual Scientific Re

Alamar Biosciences — BofA Healthcare Conference 2026 on 6ix

Alamar Biosciences — BofA Healthcare Conference 2026

Slide 1: BofA Healthcare Conference Presentation

Slide 2: Disclaimers

Slide 3: Proteomics is the new frontier in human biology and precision medicine

Slide 4: Powering precision proteomics to enable the earliest detection of disease

Slide 5: Fastest commercial ramp in proteomics

Slide 6: Q1 2026 revenue nearly doubles year-over-year

Slide 7: Massive and rapidly expanding proteomics opportunity

Slide 8: Establishing a gold standard in precision proteomics

Slide 9: Combining all five pillars required for precision proteomics

Slide 10: NULISA technology is designed to set a new standard in performance

Slide 11: Our platform: Precision Proteomics

Slide 12: One platform enabling end-to-end proteomics from discovery to diagnostics

Slide 13: Building category leadership using a proven playbook

Slide 14: Exceptional growth in a challenging macro environment

Slide 15: Example of a top pharma's journey in platform adoption

Slide 16: Strong and rapidly growing scientific publications

Slide 17: Collaborating with some of the world's most influential neuro foundations

Slide 18: Accelerating growth through a highly efficient sales team

Slide 19: Driving adoption and expansion over the next 12 months

Slide 20: Building a portfolio of differentiated assay content

Slide 21: Customer-driven menu expansion across continuum from discovery to clinical

Slide 22: Raising the bar with Neuro 220

Slide 23: What differentiates our model from other LS tools?

Slide 24: Seasoned leaders with a proven track record of success

Slide 25: Our growth strategy to lead the proteomics era

Slide 26: Alamar is well-positioned to lead precision proteomics

Slide 27: ©2026 Alamar Biosciences, Inc.